Nivolumab is effective in the treatment of classical Hodgkin lymphoma that relapsed after allogeneic hematopoietic stem cell transplantation (SCT) with the risk of graft-versus-host disease; however, the optimal time and dose of nivolumab administration remain to be investigated. Nivolumab binding to PD-1 masks flowcytometric detection of PD-1 by the anti-PD-1 monoclonal antibody EH12.1. Using this method, we monitored nivolumab binding on T cells after nivolumab treatment in a patient with classical Hodgkin lymphoma relapsed after allogeneic SCT. Nivolumab was effective while prolonged nivolumab binding was evident, but restoration of PD-1 staining predicted tumor relapse. Flowcytometric monitoring of nivolumab binding on T cells could be a promising biomarker for predicting tumor relapse and determining the timing of nivolumab administration.

中文翻译：

---

nivolumab与T细胞PD-1结合的丧失预示了霍奇金淋巴瘤的复发。

Nivolumab可有效治疗异基因造血干细胞移植（SCT）后复发的经典霍奇金淋巴瘤，且有移植物抗宿主病的风险。但是，是否需要研究诺和单抗的最佳给药时间和剂量。Nivolumab与PD-1的结合掩盖了抗PD-1单克隆抗体EH12.1对PD-1的流式细胞术检测。使用这种方法，我们在同种异体SCT复发的经典霍奇金淋巴瘤患者中监测了nivolumab治疗后nivolumab对T细胞的结合。Nivolumab是有效的，但延长了nivolumab的结合是明显的，但是PD-1染色的恢复预示了肿瘤的复发。流式细胞术监测nivolumab与T细胞的结合可能是预测肿瘤复发和确定nivolumab给药时间的有前途的生物标志物。